CY1106278T1 - 4-FLUORO-N-INDAN-2-YLATE BENZAMIDE AND ITS USE AS A PHARMACEUTICAL PREPARATION - Google Patents
4-FLUORO-N-INDAN-2-YLATE BENZAMIDE AND ITS USE AS A PHARMACEUTICAL PREPARATIONInfo
- Publication number
- CY1106278T1 CY1106278T1 CY20061101753T CY061101753T CY1106278T1 CY 1106278 T1 CY1106278 T1 CY 1106278T1 CY 20061101753 T CY20061101753 T CY 20061101753T CY 061101753 T CY061101753 T CY 061101753T CY 1106278 T1 CY1106278 T1 CY 1106278T1
- Authority
- CY
- Cyprus
- Prior art keywords
- indan
- benzamide
- fluoro
- pharmaceutical preparation
- diabetes
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 abstract 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 200000000007 Arterial disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 201000001068 Prinzmetal angina Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 201000004239 Secondary hypertension Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 208000007718 Stable Angina Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000006386 memory function Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- BOFMSBVSYVESTM-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-2-yl)-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1CC2=CC=CC=C2C1 BOFMSBVSYVESTM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Abstract
Η παρούσα ευρεσιτεχνία σχετίζεται με το 4-φθορο-Ν-ινδαν-2-υλικό βενζαμίδιο του τύπου (I) και την χρήση του ως φαρμακευτικού σκευάσματος. Η ένωση (I) δύναται να χρησιμοποιηθεί για την θεραπεία και την προφύλαξη των καρδιαγγειακών νόσων όπως είναι η σταθερή ή ασταθής στηθάγχη, στηθάγχη Prinzmetal (σπασμός), οξύ στεφανιαίο σύνδρομο, καρδιακή ανεπάρκεια, έμφραγμα του μυοκαρδίου, εγκεφαλικό, θρόμβωση, περιφερική αποφρακτική αρτηριοπάθεια PAOD, αθηροσκλήρωση, επαναστένωση, τραυματισμός του ενδοθηλίου μετά από PTCA, ιδιοπαθής υπέρταση, πνευμονική υπέρταση, δευτεροπαθής υπέρταση, νεφροαγγειακή χρόνια γλουμερουλονεφρίτιδα, στυτική δυσλειτουργία, κοιλιακή αρρυθμία, και την μείωση του καρδιαγγειακού κινδύνου στις γυναίκες μετά την εμμηνόπαυση ή μετά από την πρόσληψη αντισύλληψης, την θεραπεία και προφύλαξη του διαβήτη καθώς και τις επιπλοκές του διαβήτη (νεφροπάθεια, ρετινοπάθεια), αγγειογένεση, βρογχικό άσθμα, χρόνια νεφρική ανεπάρκεια, κίρρωση του ήπατος, περιορισμένη λειτουργία μνήμης ή περιορισμένη ικανότητα μάθησης.The present invention relates to 4-fluoro-N-indan-2-yl benzamide of formula (I) and its use as a pharmaceutical preparation. Compound (I) can be used for the treatment and prophylaxis of cardiovascular diseases such as stable or unstable angina, Prinzmetal's angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral occlusive arterial disease PAOD , atherosclerosis, restenosis, endothelial injury after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, nephrovascular chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, and the reduction of cardiovascular risk in postmenopausal women or after taking contraception, the treatment and prevention of diabetes as well as the complications of diabetes (nephropathy, retinopathy), angiogenesis, bronchial asthma, chronic renal failure, cirrhosis of the liver, limited memory function or limited learning ability.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01102852 | 2001-02-13 | ||
| EP02722066A EP1361882B1 (en) | 2001-02-13 | 2002-02-12 | 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical |
| PCT/EP2002/001443 WO2002064146A1 (en) | 2001-02-13 | 2002-02-12 | 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106278T1 true CY1106278T1 (en) | 2011-10-12 |
Family
ID=8176423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101753T CY1106278T1 (en) | 2001-02-13 | 2006-12-06 | 4-FLUORO-N-INDAN-2-YLATE BENZAMIDE AND ITS USE AS A PHARMACEUTICAL PREPARATION |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US6617359B2 (en) |
| EP (1) | EP1361882B1 (en) |
| JP (1) | JP4317689B2 (en) |
| KR (1) | KR101017531B1 (en) |
| CN (1) | CN100553631C (en) |
| AT (1) | ATE344669T1 (en) |
| AU (1) | AU2002253009B2 (en) |
| BG (1) | BG66065B1 (en) |
| BR (1) | BR0207178A (en) |
| CA (1) | CA2437966C (en) |
| CY (1) | CY1106278T1 (en) |
| CZ (1) | CZ20032154A3 (en) |
| DE (1) | DE60215919T2 (en) |
| DK (1) | DK1361882T3 (en) |
| EE (1) | EE05302B1 (en) |
| ES (1) | ES2274025T3 (en) |
| HK (1) | HK1062140A1 (en) |
| HR (1) | HRP20030646A2 (en) |
| HU (1) | HUP0302845A3 (en) |
| IL (2) | IL157208A0 (en) |
| MX (1) | MXPA03006841A (en) |
| MY (1) | MY135778A (en) |
| NO (1) | NO333522B1 (en) |
| NZ (1) | NZ527469A (en) |
| PE (1) | PE20020884A1 (en) |
| PL (1) | PL363452A1 (en) |
| PT (1) | PT1361882E (en) |
| RS (1) | RS51645B (en) |
| RU (1) | RU2308946C2 (en) |
| SI (1) | SI1361882T1 (en) |
| SK (1) | SK286513B6 (en) |
| TW (1) | TWI241190B (en) |
| WO (1) | WO2002064146A1 (en) |
| ZA (1) | ZA200305412B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| TWI241190B (en) * | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| PE20020870A1 (en) * | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL ACILATED AMINES |
| EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| EP1388342A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| US7105513B2 (en) * | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US20040167211A1 (en) | 2002-10-21 | 2004-08-26 | Xiiaoli Chen | Methods of using substituted tetralins and indanes |
| EP1581510A4 (en) * | 2002-11-22 | 2006-08-30 | Bristol Myers Squibb Co | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
| US7132536B2 (en) * | 2003-04-24 | 2006-11-07 | Sanofi-Aventis Deutschland Gmbh | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals |
| EP1644320B1 (en) * | 2003-07-03 | 2008-01-16 | Eli Lilly And Company | Indane derivates as muscarinic receptor agonists |
| WO2005018620A2 (en) * | 2003-08-26 | 2005-03-03 | Cell Center Cologne Gmbh | Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction |
| EP1529525A1 (en) * | 2003-11-06 | 2005-05-11 | Aventis Pharma Deutschland GmbH | ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases |
| US8309608B2 (en) * | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| PL1708690T3 (en) * | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Treatment of phenylketonuria with bh4 |
| AR048931A1 (en) | 2004-04-21 | 2006-06-14 | Janssen Pharmaceutica Nv | PROCESS FOR THE PREPARATION OF SUBSTITUTED AND INDIAN TETRALIN DERIVATIVES AND PREPARATION OF SYNTHESIS INTERMEDIARIES |
| WO2006055511A2 (en) * | 2004-11-17 | 2006-05-26 | Biomarin Pharmaceutical Inc. | Stable tablet formulation of tetrahydrobiopterin |
| EP1814553A4 (en) | 2004-11-19 | 2009-10-28 | Childrens Hosp Medical Center | Gtpase inhibitors and use thereof for controlling platelet hyperactivity |
| US20060185492A1 (en) | 2005-02-18 | 2006-08-24 | Francois Chianese | Shoulder bushing for saw blades |
| EP1741709A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| US7795101B2 (en) * | 2006-04-03 | 2010-09-14 | United Microelectronics Corp. | Method of forming a MOS transistor |
| EP1905764A1 (en) | 2006-09-30 | 2008-04-02 | Sanofi-Aventis | Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals |
| EP1923062A1 (en) | 2006-11-16 | 2008-05-21 | sanofi-aventis | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals |
| KR101349187B1 (en) * | 2006-12-05 | 2014-01-10 | (주)아모레퍼시픽 | Pharmaceutical composition for treating and preventing lipid metabolism-related diseases |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| EP1939181A1 (en) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
| EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
| EP1964840A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
| US20160169868A9 (en) * | 2007-05-24 | 2016-06-16 | Calcimedica, Inc. | Calcium channel proteins and uses thereof |
| RU2487710C2 (en) * | 2007-10-09 | 2013-07-20 | Новартис Аг | Pharmaceutical composition of valsartan |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| UY33476A (en) | 2010-06-30 | 2012-02-29 | Ironwood Pharmaceuticals Inc | SGC STIMULATORS |
| RU2582679C2 (en) | 2010-11-09 | 2016-04-27 | Айронвуд Фармасьютикалз, Инк. | sGC STIMULATORS |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| CN106117194A (en) | 2011-12-27 | 2016-11-16 | 铁木医药有限公司 | Can be used as 2 benzyls of SGC stimulant, 3 (pyrimidine 2 base) substituted pyrazoles |
| US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| US9487508B2 (en) | 2012-09-19 | 2016-11-08 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| LT3660013T (en) | 2013-03-15 | 2022-04-11 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| CA2933250A1 (en) | 2013-12-11 | 2015-06-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
| CN107406422B (en) | 2014-09-17 | 2022-02-01 | 赛科理音医疗有限公司 | Pyrazole derivatives as sGC stimulators |
| EP3194386A2 (en) | 2014-09-17 | 2017-07-26 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| WO2018009596A1 (en) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Phosphorus prodrugs of sgc stimulators |
| EA039753B1 (en) | 2016-07-07 | 2022-03-10 | Сайклерион Терапьютикс, Инк. | SOLID FORMS OF AN sGC STIMULATOR |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180597B1 (en) | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
| WO2000003746A2 (en) | 1998-07-14 | 2000-01-27 | The Brigham And Women's Hospital, Inc. | Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
| AUPP891299A0 (en) * | 1999-02-26 | 1999-03-25 | Fujisawa Pharmaceutical Co., Ltd. | New 6-membered cyclic compounds |
| EP1289526A4 (en) * | 2000-05-30 | 2005-03-16 | Merck & Co Inc | Melanocortin receptor agonists |
| PE20020870A1 (en) * | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL ACILATED AMINES |
| TWI241190B (en) * | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| PE20020856A1 (en) * | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-TETRAHYDRONAFTIL ACILATED AMINES |
| US7186735B2 (en) * | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| US7338956B2 (en) * | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7105513B2 (en) * | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| US8309608B2 (en) * | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
-
2002
- 2002-02-08 TW TW091102292A patent/TWI241190B/en not_active IP Right Cessation
- 2002-02-11 MY MYPI20020481A patent/MY135778A/en unknown
- 2002-02-12 BR BR0207178-9A patent/BR0207178A/en not_active Application Discontinuation
- 2002-02-12 WO PCT/EP2002/001443 patent/WO2002064146A1/en active IP Right Grant
- 2002-02-12 DK DK02722066T patent/DK1361882T3/en active
- 2002-02-12 IL IL15720802A patent/IL157208A0/en unknown
- 2002-02-12 MX MXPA03006841A patent/MXPA03006841A/en active IP Right Grant
- 2002-02-12 KR KR1020037010490A patent/KR101017531B1/en not_active IP Right Cessation
- 2002-02-12 ES ES02722066T patent/ES2274025T3/en not_active Expired - Lifetime
- 2002-02-12 CA CA2437966A patent/CA2437966C/en not_active Expired - Fee Related
- 2002-02-12 DE DE60215919T patent/DE60215919T2/en not_active Expired - Lifetime
- 2002-02-12 SI SI200230443T patent/SI1361882T1/en unknown
- 2002-02-12 PT PT02722066T patent/PT1361882E/en unknown
- 2002-02-12 NZ NZ527469A patent/NZ527469A/en not_active IP Right Cessation
- 2002-02-12 CN CNB028048636A patent/CN100553631C/en not_active Expired - Fee Related
- 2002-02-12 EP EP02722066A patent/EP1361882B1/en not_active Expired - Lifetime
- 2002-02-12 JP JP2002563939A patent/JP4317689B2/en not_active Expired - Fee Related
- 2002-02-12 RU RU2003127750/15A patent/RU2308946C2/en not_active IP Right Cessation
- 2002-02-12 SK SK1011-2003A patent/SK286513B6/en not_active IP Right Cessation
- 2002-02-12 CZ CZ20032154A patent/CZ20032154A3/en unknown
- 2002-02-12 HU HU0302845A patent/HUP0302845A3/en unknown
- 2002-02-12 AT AT02722066T patent/ATE344669T1/en active
- 2002-02-12 EE EEP200300368A patent/EE05302B1/en not_active IP Right Cessation
- 2002-02-12 RS YU61703A patent/RS51645B/en unknown
- 2002-02-12 AU AU2002253009A patent/AU2002253009B2/en not_active Ceased
- 2002-02-12 PL PL02363452A patent/PL363452A1/en not_active Application Discontinuation
- 2002-02-13 PE PE2002000123A patent/PE20020884A1/en not_active Application Discontinuation
- 2002-02-13 US US10/073,330 patent/US6617359B2/en not_active Expired - Lifetime
-
2003
- 2003-07-14 ZA ZA200305412A patent/ZA200305412B/en unknown
- 2003-07-15 BG BG107994A patent/BG66065B1/en unknown
- 2003-07-22 US US10/623,775 patent/US6812253B2/en not_active Expired - Lifetime
- 2003-08-03 IL IL157208A patent/IL157208A/en not_active IP Right Cessation
- 2003-08-11 NO NO20033546A patent/NO333522B1/en not_active IP Right Cessation
- 2003-08-12 HR HR20030646A patent/HRP20030646A2/en not_active Application Discontinuation
-
2004
- 2004-06-11 HK HK04104235.3A patent/HK1062140A1/en not_active IP Right Cessation
- 2004-08-18 US US10/920,395 patent/US7202278B2/en not_active Expired - Lifetime
-
2006
- 2006-12-06 CY CY20061101753T patent/CY1106278T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106278T1 (en) | 4-FLUORO-N-INDAN-2-YLATE BENZAMIDE AND ITS USE AS A PHARMACEUTICAL PREPARATION | |
| BR0207197A (en) | Acylated 6,7,8,9-tetrahydro-5h-benzocycloeptenyl amines and their use as a pharmaceutical agent | |
| DK1370530T3 (en) | Acylated 1,2,3,4-tetrahydronaphthylamines and their use as pharmaceuticals | |
| TNSN03044A1 (en) | Acylated indanyl amines and their use as pharmaceuticals | |
| WO2004020410A3 (en) | Dihydropyridinone derivatives as hne inhibitors | |
| WO2001074793A3 (en) | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 | |
| ES2141197T3 (en) | DERIVATIVES OF PHENOXYPHENYLACETIC ACID. | |
| UY26926A1 (en) | DERIVATIVES OF QUINOLINE AND QUINAZOLINE | |
| NO20040234L (en) | Substituted piperazine compounds and their use as inhibitors of oxidation of fatty acids | |
| ATE338549T1 (en) | THERAPEUTIC COMPOSITION OF AMLODIPINE AND BENAZEPRIL / BENAZEPRILATE | |
| BR0008310A (en) | Alpha-Alanine derivatives | |
| BR9914893A (en) | Chromenone and chromanone derivatives as integrin inhibitors | |
| SE0003795D0 (en) | Pharmaceutically useful compounds | |
| AR035538A1 (en) | 4-FLUORO-N-INDAN-2-IL-BENZAMIDA FOR THE MANUFACTURE OF A PHARMACEUTICAL MEDICINAL COMPOSITION AND COMPOSITIONS | |
| ATE365737T1 (en) | SUBSTITUTED PIPERAZINE COMPOUNDS AND THE USE THEREOF AS FATTY ACID OXIDATION INHIBITORS | |
| AR006408A1 (en) | DERIVED FROM BUTADIENE, DERIVED FROM AMIDOBUTADIENE, DERIVED FROM PIRROLIDINE AND PREPARATION PROCESSES THEREOF. | |
| AR025645A1 (en) | USE OF TIENOPIRIMIDINS | |
| BR0113373A (en) | Biphenyl derivatives and their use as integrin inhibitors | |
| PA8551901A1 (en) | INDANIL ACILATED AMINAS AND ITS USE AS PHARMACOS | |
| PA8552101A1 (en) | 6,7,8,9-TETRAHIDRO-5H-BENZOCICLOHEPTENIL ACILATED AMINES AND ITS USE AS PHARMACOS |